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Background: Androgen deprivation therapy is the primary strategy for the treatment of advanced prostate cancer;
however, after an initial regression, most patients will inevitably develop a fatal androgen-independent tumor.
Therefore, understanding the mechanisms of the transition to androgen independence prostate cancer is critical to
identify new ways to treat older patients who are ineligible for conventional chemotherapy.
Methods: The effects of 5-Aza-2’-deoxycytidine (5-Aza-CdR) on the viability and the apoptosis of the androgen-
dependent (LNCaP) and androgen-independent (PC3) cell lines were examined by MTS assay and western blot analysis
for the activation of caspase-3. The subcutaneous LNCaP xenografts were established in a nude mice model. MiR-146a
and DNMTs expressions were analyzed by qRT-PCR and DNA methylation rates of LINE-1 were measured by COBRA-IRS
to determine the global DNA methylation levels. The methylation levels of miR-146a promoter region in the different
groups were quantified by the bisulfite sequencing PCR (BSP) assay.
Results: We validated that 5-Aza-CdR induced cell death and increased miR-146a expression in both LNCaP and PC3 cells.
Notably, the expression of miR-146a in LNCaP cells was much higher than in PC3 cells. MiR-146a inhibitor was shown to
suppress apoptosis in 5-Aza-CdR-treated cells. In a castrate mouse LNCaP xenograft model, 5-Aza-CdR significantly
suppressed the tumors growth and also inhibited prostate cancer progression. Meanwhile, miR-146a expression was
significantly enhanced in the tumor xenografts of 5-Aza-CdR-treated mice and the androgen-dependent but not the
androgen-independent stage of castrated mice. In particular, the expression of miR-146a was significantly augmented in
both stages of the combined treatment (castration and 5-Aza-CdR). Additionally, the methylation percentage of the two
CpG sites (−444 bp and −433 bp), which were around the NF-κB binding site at miR-146a promoter, showed the lowest
methylation levels among all CpG sites in the combined treatment tumors of both stages.
Conclusion: Up-regulating miR-146a expression via the hypomethylation of the miR-146a promoter by 5-Aza-CdR was
correlated with delayed progression of castration-resistant prostate cancers. Moreover, site-specific DNA methylation may
play an important role in miR-146a expression in androgen-dependent prostate cancer progression to androgen-
independent prostate cancer and therefore provides a potentially useful biomarker for assessing drug efficacy in prostate
cancer.
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Prostate cancer is the most common malignant tumor in
men in many industrialized nations and is the second
highest cause of cancer mortality [1]. As prostate cancer
relies on androgens for its maintenance and progres-
sion, targeting androgens offers a therapeutic opportu-
nity to halt or delay the progression of prostate cancer.
Androgen-deprivation therapies, including castration
(orchiectomy, the surgical removal of the testicles) and
pharmacological control, are the mainstay for the man-
agement of advanced prostate cancer, reducing symp-
toms in approximately 70–80% of patients. Regardless,
most tumors relapse within two years to an incurable
hormone-independent state, in which tumor cells are
scarcely responsive to even high concentrations of che-
motherapeutic agents or radiotherapy [2]. The regula-
tory mechanisms that cause this transition remain
largely unknown, and no effective therapy for androgen-
independent prostate cancer (AIPC) has been developed
to date.
DNA methylation is an important regulator of gene
transcription and plays an important role in the process
of tumorigenesis and the development of prostate cancer
[3,4]. 5-Aza-2’-deoxycytidine (5-Aza-CdR), a nucleoside
analog inhibitor of DNA methyltransferase (DNMT), has
been used to reverse methylation and reactivate the ex-
pression of silenced genes [5]. 5-Aza-CdR was able to
suppress the growth of various tumors in vitro, animal
models, and clinical trials including prostate cancer
[6-9], hematopoietic malignancies [10,11], and lung car-
cinoma [12]. In vitro studies investigating the effects of
5-aza-CdR in prostate cancer cell lines demonstrated
that a low-dose 5-aza-CdR treatment regimen given
daily completely inhibited cell proliferation and induced
cell death in LNCaP and PC3 cell lines [13]. Moreover,
several studies have been conducted to examine the syn-
ergistic effects of 5-Aza-CdR and chemotherapeutic
agents against tumor cells. A combination of 5-Aza-CdR
and cisplatin showed synergy in triggering the apoptotic
death of PC3 cells [14], and the combined treatment of
castration and 5-Aza-CdR was more effective than either
treatment alone according to tissue histology, signifi-
cantly prolonging survival in a transgenic adenocarcin-
oma mouse model of prostate cancer [9]. Nevertheless,
it remains unknown whether 5-Aza-CdR can delay the
progression of castration-resistant prostate cancer, and
little is known about the genes silenced in progressed
prostate cancer cells that are reactivate by 5-Aza-CdR.
MicroRNAs (miRNAs) are a class of short (between 19
and 25 nucleotides) noncoding RNAs that negatively regu-
late gene expression via complementary binding to target
messenger RNA (mRNA) [15], thereby impairing the trans-
lation of the mRNA or marking it for early degradation.
Dysregulated miRNA expression plays an important rolein the process of tumorigenesis and development of
androgen-independent tumors after castration in prostate
cancer patients [16]. A recent study reported that the ex-
cessive expression of miR-146a was exclusively found in
prostate cancer LNCaP and PC3 cell lines [17]. Transfec-
tion of miR-146a into a cell line was found to significantly
suppress the expression of ROCK1, consequently markedly
reducing cell proliferation, invasion, and metastasis to hu-
man bone marrow endothelial cell monolayers [17,18], indi-
cating that miR-146a may function as a tumor-suppressor
gene in the transformation of AIPC and metastasis in pros-
tate cancer.
In the present study, we found that 5-Aza-CdR could
inhibit the cell viability of either androgen-dependent
LNCaP cells or androgen-independent PC3 cells through
the up-regulation of miR-146a expression. To evaluate
the effect of 5-Aza-CdR on the progression of AIPC
in vivo, we established subcutaneous LNCaP xenografts
in castrated male mice. As expected, 5-Aza-CdR delayed
the progression of castration-resistant tumors. The
methylation levels of the global genome and miR-146a
promoter were decreased after 5-Aza-CdR treatment,
which resulted in the increased expression of miR-146a,
suggesting that castration in combination with 5-Aza-CdR
may be a new therapeutic option for both androgen-
dependent and -independent prostate cancer.Methods
Cell culture and treatment
LNCaP and PC3 human prostate carcinoma cells (American
Type Culture Collection, ATCC) were maintained in
RPMI 1640 supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 pg/ml streptomycin
(Gibco, NY, USA). 5-Aza-CdR (Sigma-Aldrich, St.
Louis, Mo, USA) was dissolved in dimethylsulfoxide
(DMSO). Fresh medium containing 5-Aza-CdR was re-
placed every 24 h. MiR-146a inhibitors (single-stranded
chemically modified oligonucleotides; Life Technologies
Corporation, Shanghai, China) were used for the inhib-
ition of miR-146a expression in LNCaP and PC3 cells.
Negative control inhibitors (ctrl inhibitors) were trans-
fected as matched controls. Cells were transfected with
RNAs using INTERFERin (Polyplus-Transfection SA,
Illkirch, France) according to the manufacturer’s
instructions.Cell viability assays
LNCaP and PC3 cells were seeded in 96-well culture
plates with 100 μl of growth medium. Following 5-Aza-
CdR or miR-146a inhibitor treatment, MTS cell viability
assays were performed according to the manufacturer’s
instructions.
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Male BALB/c nude mice at 4–6 weeks age (18–20 g)
were obtained from the Institute of Zoological Sciences,
Chinese Academy of Medical Sciences in Beijing. For the
tumor growth studies, 5 × 106 LNCaP cells in 0.1 ml sus-
pension were mixed with 0.1 ml of Matrigel (Collabora-
tive Research Inc., Bedford, MA, USA) and inoculated
into the right dorsal flanks of the mice. When the tumor
volumes reached approximately 250 mm3, the animals
were randomly divided into four groups (n = 12). One
was administered thrice weekly on consecutive days in-
traperitoneal (i.p.) injections of 0.25 mg/kg 5-Aza-CdR
dissolved in PBS. Two groups underwent bilateral orchi-
ectomy (castration) under metofane (Pitman-Moore,
Washington Crossing, NJ) anesthesia. Three days after
surgery, these two groups were injected with either 5-
Aza-CdR or PBS thrice weekly i.p. The control mice
were testis-intact animals, with injections of PBS. The
tumor volume was measured with calipers twice weekly
for length and width; the volume was then calculated by
the formula: [(length × width2)/2]. The animals of each
group were euthanized on the 14th and 35th day post-
treatment (n = 6 per group at either time point), respect-
ively. All animal experiments were approved by the
Committee of Use and Care of Animals, Chinese Acad-




















F, forward primer; R, reverse primer.Measurement of miRNA and mRNA expression
The small and total RNA fractions were isolated isolated
from cells and tumor tissue using the miRVana miRNA
Isolation Kit (Ambion Inc, Austin, TX, USA) according
to the manufacturer’s instructions. MiRNA was reverse-
transcribed using the TaqMan microRNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA,
USA) in a reaction mixture containing an miR-specific
stem-loop reverse transcription (RT) primer. The Taq-
man miRNA assay system (Applied Biosystems, Foster
City, CA) was used according to the manufacturer’s in-
structions to quantitatively detect the expression of ma-
ture miRNAs was performed using the TaqMan miRNA
Assay Kit (Applied Biosystems) containing TaqMan
primers in a universal PCR master mix. CDNA was syn-
thesised by reversetranscription using ReverTra Ace
(Toyobo, Osaka, Japan). The SYBR Green PCR Master
Mix (Toyobo, Osaka, Japan) was used to analyze mRNA
expression. Quantification of miRNAs and mRNA by
qRT-PCR was performed using an ABI 7300HT thermo-
cycler (Applied Biosystems) at 95°C for 10 min, followed
by 40 cycles of 95°C for 15 s and 60°C for 1 min. Reac-
tions were performed in triplicate with human U6 or
GAPDH as an internal control. The primer sequences
for real-time quantitative PCR (qRT-PCR) are shown in
Table 1. Fluorescent signals were normalized to aninternal reference, and the threshold cycle was set within
the exponential phase of PCR. The tumor tissue from
the control mice of the first analysis was used to the
calibrator samples. The relative gene expression was cal-
culated by comparing cycles for each target PCR. Cycle
threshold values were converted to relative gene expres-
sion levels using the 2-ΔΔCT method.
Western blot analysis
Cells were lysed for 30 min at 4°C in PBS with 1%
NP-40 and protease inhibitor cocktail tablets (Roche,
Mannheim, Germany). Protein concentration was assa-
yed by using bicinchoninic acid (Pierce, Rockford, IL).
Total proteins were separated by electrophoresis on 12%
SDS-polyacrylamide gels and 4% polyacrylamide gels
and transferred to nitrocellulose. Immunodetection of
caspase 3 and GAPDH was carried out by using anti-
caspase 3 antibody at a dilution of 1:400 and anti-
GAPDH (Cell Signaling Technology, Inc., Beverly, MA,
USA). Specific proteins were visualized with enhanced
chemiluminescence reagents (Hyperfilm ECL; Amersham
Biosciences, Buckinghamshire, England) followed by ex-
posure to X-ray film for 1 to 3 min.ELISA assay
Blood samples were collected by tail vein incision, and
the serum was stored at −20°C until assayed. The free
prostate-specific antigen (FPSA) in mouse serum was
measured using ELISA kits (R&D Systems, USA) accord-
ing to the manufacturer’s protocol.
COBRA assay
The bisulfite modification of genomic DNA was performed
using the CpGenome Turbo Bisulfite Modification Kit
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LINE-1 repetitive elements was performed initially using
the COBRA assay. The primer sequences that correspond
to the nucleotides in the regulatory region of the LINE-
1sequence are shown in Table 1. The PCR reactions con-
sisted of 35 cycles of 95°C for 1 min, 53°C for 1 min, and
72°C for 1 min. The PCR products were subsequently
digested with TaqI (MBI Fermentas) and TasI (MBI Fer-
mentas) in TE buffer3 (Biolab) at 65°C overnight and then
separated by electrophoresis on polyacrylamide gels. The
gel was stained by silver staining. The methylated bands of
LINE-1 (TaqI positive) yielded two 80-bp DNA fragments,
whereas the unmethylated amplicons (TasI positive) yielded
63- and 97-bp fragments. The methylation levels were cal-
culated as the intensity of methylated bands divided by the
sum of the methylated and unmethylated bands. Each
COBRA assay was performed two to four times.
Quantification of the methylation levels of the miR-146a
promoter
The miR-146a promoter regions essential for basal tran-
scriptional activity occur between nt −442 and nt +5 and
include 11 CpG sites. The 447-bp region was amplified
by bisulfite specific PCR (BSP) using primers designed
with the MethPrimer software (Table 1). The PCR reac-
tion contained modified genomic DNA and was overlaid
with mineral oil to form a vapor barrier. The cycling
conditions consisted of an initial denaturation at 96 ºC
for 5 min after which 0.5 μl reverse primer (10 μM) was
added to the PCR mixture, followed by 2 cycles of 96°C
for 1 min, 58°C for 2 min, and 72°C for 2 min. When
the temperature again rose to 96°C, which was at the be-
ginning of the next phase of 8 cycles (96°C for 1 min,
58°C for 2 min, and 72°C for 2 min), 0.5 μl forward pri-
mer was added to the mixture. Then, 30 cycles of 96°C
for 30 s, 55°C for 45 s, and 72°C for 45 s were per-
formed, followed by a final extension of 72 ºC for 7 min.
The PCR products were sequenced using a DNA se-
quencer (ABI PRISM 3730, Foster City, CA, USA), and
the methylation levels were measured according to our
previously reported method [19].
Statistical analysis
All the data were obtained from at least three independ-
ent experiments. The data were expressed as the mean
values ± SD and compared between two groups using
Student’s t-test. The statistical significance was defined
as a P value less than 0.05.
Results
5-Aza-CdR-induced miR-146a expression promoted apop-
tosis in LNCaP and PC3 cells
We firstly examined the effects of 5-Aza-CdR on the viabil-
ity of the LNCaP and PC3 cell lines using an MTS analysis.As shown in Figure 1A and B, treatment with 10 to 200
nM 5-Aza-CdR for 6 days induced cell death in a dose-
dependent manner in both cell lines; 20 nM, 50 nM, and
100 nM 5-Aza-CdR caused 40%, 60%, and 75% reductions,
respectively, in cell viability (as shown by white bars). To
determine whether 5-Aza-CdR could effectively inhibit
prostate cancer cell growth by induction of apoptosis, we
examined the activition of caspase-3 in LNCaP and PC3
cells. As shown in Figure 1C, 5-Aza-CdR treatment re-
sulted in significant increases in cleavage of caspase-3,
which indicated that the mitochondrial apoptotic pathway
was activated. The results indicated that both androgen-
dependent and androgen-independent prostate cancer cell
lines were susceptible to 5-Aza-CdR cytotoxicity.
Recent studies have demonstrated that the aberrant
expression of miRNAs is closely associated with the de-
velopment, invasion, metastasis, and prognosis of pro-
state cancer. MiR-146a was demonstrated to act as
a tumor-suppressor gene in prostate cancer. Thus, to
clarify the potential mechanism of 5-Aza-CdR, we deter-
mined whether miR-146a played an important role in 5-
Aza-CdR-induced apoptosis in prostate cancer cells. As
shown in Figure 1D, there was a dosage-dependent in-
duction of miR-146a expression in both LNCaP and PC3
cells when treated with 5-Aza-CdR (as shown by white
bars), with the expression of miR-146a in untreated
LNCaP cells twice that in untreated PC3 cells. To esti-
mate whether the effect of 5-Aza-CdR treatment on
miR-146a expression was associated with the demethyla-
tion of miR-146a promoter, we analyzed the methylation
status of miR-146a promoter region upon 5-Aza-CdR
administration to LNCaP cells by BSP assay. As shown
in Figure 1E, 5-Aza-CdR was downregulated twofold
compared with the untreated cells. The result suggests
that miR-146a expression was associated with its pro-
moter methylation status.
To further confirm the association of increased miR-
146a levels and 5-Aza-CdR-mediated apoptosis, the
prostate cancer cells were transfected with miR-146a in-
hibitors and then treated with 5-Aza-CdR. We firstly ex-
amined the effects of knockdown of miR-146a in control
and 5-Aza-CdR-treated cells. MiR-146a inhibitors sig-
nificantly down-regulated the miR-146a expression level
(P < 0.01) in both prostate cancer cells either untreated
or treated by 5-Aza-CdR (Figure 1D) (as shown by gray
bars). As shown in Figure 1A and B, miR-146a inhibitors
significantly increased cell viability after 5-Aza-CdR
treatment compared to the controls (as shown by gray
bars). Additionally, treatment with miR-146a inhibitors
significantly prevented 5-Aza-CdR-induced caspase-3 ac-
tivation in both cell lines (Figure 1C), indicating that
miR-146a played an important role in 5-Aza-CdR-in-
duced cell death in prostate cancer cells, regardless of
androgen dependency.
Figure 1 The effect of 5-Aza-CdR and miR-146a inhibitors on the viability and apoptosis of LNCaP and PC3 prostate cancer cells. LNCaP
and PC3 prostate cancer cells transfected with the miR-146a inhibitor or control inhibitor were treated with increasing doses of 5-aza-CdR,
replenished daily for up to 6 days. The relative cell viability was measured by the MTS assay (A-B) and apoptosis was detected by western blot
analysis for the activation of caspase-3 (C). MiR-146a expression was measured by qRT-PCR in LNCaP and PC3 cells treated with 5-Aza-CdR at
various concentrations for 4 days transfected with control inhibitor or miR-146a inhibitor (D). DNA methylation levels of miR-146a promoter
region in 5-Aza-CdR-treated LNCaP cells by BSP assay (E). The data represent the mean ± SD of triplicate wells from at least two experiments. *P
< 0.05 and **P < 0.01 compared to the control.
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LNCaP xenograft model of castrated mice
To further investigate whether 5-Aza-CdR can delay
prostate cancer progression, we establish subcutaneous
LNCaP xenografts in a nude mice model. When the vol-
ume of xenografts reached to 250 mm3, the mice were
randomly divided into 4 groups (n = 12) and treated with
PBS as a control, 5-Aza-CdR, castration, or the combin-
ation of 5-Aza-CdR plus castration. After the 3rd day
post-castration treatment, the tumors volumes began to
decrease in both the castration treatment group and
combination groups. On the 17th day of post-castration
treatment, the tumor volumes in the castration group
were reduced by 80%, to a much greater extent than in
the control mice (Figure 2A); up to 17 days, tumor
growth was considered in the regression stage. There-
after, the tumors of the castration group began to grow
uncontrollably. On the 35th day of post-castrationtreatment, the tumor size in the castration group was
inhibited only by 45%; from 17 days to 35 days, the
tumor growth was considered in the regeneration stage.
The tumor growth in the combination group remained
suppressed throughout this period, with the tumor size
inhibited by 86% and 81% on the 17th and 35th days, re-
spectively. In the 5-Aza-CdR treatment group, the tu-
mors began to significantly grow more slowly than in
the control group from the 10th day of post-treatment.
On the 35th day of post-treatment, the tumor size in the
5-Aza-CdR group was inhibited by 41% compared to the
control group.
The animals of the four groups were euthanized on
the 14th and 30th days after castration, and the xeno-
grafts tissues were removed for the first analysis (n = 6)
and the second analysis (n = 6), respectively. The tumor
weights in the combination group were significantly
lower than that treated with either therapy alone
Figure 2 Synergistic antitumor effect of the combination of 5-Aza-CdR and castration in vivo. LNCaP cells were inoculated into the right
thighs of BALB/c nude mice. When the tumor size reached to 250 mm3, the mice received an intraperitoneal injection of PBS (control), 5-Aza-CdR
(0.25 mg/kg) thrice weekly, castration, or the combination of castration and 5-Aza-CdR (n = 12 per group). The tumor volume was monitored
every two or three days (A). The animals were euthanized on days 14 and 35 post-treatment (n = 6 per group at either time point) for DNA, RNA,
and protein analyses. The tumor weights were determined (B). PSA release into serum was measured by an ELISA analysis (C). The data are the
mean ± SD of one representative experiment. Similar results were obtained in three independent experiments. *P < 0.05, **P < 0.01 compared to
the control mice.
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analysis (Figure 2B).
To further assess the effects of 5-Aza-CdR on the
transition of prostate cancer, we examined the free
prostate-specific antigen (FPSA) concentrations, an im-
portant clinical parameter for screening and testing
prostate cancer [20]. The results showed that the trend
of FPSA concentration in the combination treatment
was the lowest among the different groups in both
analyses, similar to the tumor sizes and weights
(Figure 2C). These data demonstrated that combination
of 5-Aza-CdR and castration effectively suppressed theregeneration of castration-resistant prostate cancer in a
nude mice model.
MiR-146a expression was associated with tumor growth
in the prostate cancer xenograft mouse model
MiR-146a expression in the xenograft tissues was de-
tected by a qRT-PCR analysis. As shown in Figure 3,
miR-146a levels in the 5-Aza-CdR-treated tumor tissue
were significantly increased by approximately 2-fold at
the first analysis and 4-fold at the second analysis com-
pared to the controls, indicating that 5-Aza-CdR could
effectively induce miR-146a expression in the prostate
Figure 3 miR-146a expression in human prostate cancer
xenograft mouse models. The miR-146a level was detected using
qRT-PCR and described as the fold-change after normalization to U6
RNA in the tumor tissues of different mice groups (n = 6). The tumor
tissue from the control mice of the first analysis was used to the
calibrator samples. The data are the mean ± SD of one representative
experiment. Similar results were obtained in three independent
experiments. *P < 0.05, **P < 0.01 compared to the control samples.
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the castrated mice, the miR-146a levels were also signifi-
cantly increased by 3-fold in the regression stage but no
different in the regeneration stage compared to the con-
trol. MiR-146a expression was at the highest levels in
the combination group tissues, 7-fold at the former stage
and 6-fold at the latter stage compared to the control
mice, indicating a combined effect of 5-Aza-CdR and
castration on miR-146a expression. The results sug-
gested that miR-146a expression was negatively corre-
lated with tumor growth in prostate cancer xenografts.
The global DNA methylation levels were different among
the different groups
To determine whether the treatments of 5-Aza-CdR and
castration affected the global DNA methylation levels,
we first detected DNMTs expression in the tumor tis-
sues dissected from the xenografts to assay the global
DNA methylation levels. As shown in Figure 4A, in the
tissues of the first analysis, the expression of DNMTs
was all slightly decreased in the 5-Aza-CdR-treatment
groups (P > 0.05), whereas they were all significantly de-
creased in both the castration alone (P < 0.01) and com-
bination group (P < 0.01). At the second analysis, the
DNMT levels were mostly unchanged in the 5-Aza-
CdR-treated mice (P > 0.05). In contrast, DNMT3a was
decreased in the castrated mice (P < 0.05), and DNMT1
and DNMT3b were both significantly decreased in the
combination group (P < 0.01 and P < 0.05, respectively),
which was not consistent with the tumor sizes in the dif-
ferent groups.To further confirm the global DNA methylation
levels, we analyzed the DNA methylation of LINE-1, a
surrogate marker of genome-wide methylation changes,
by COBRA-IRS [21]. An outline and the principal of
COBRA LINE-1 are illustrated in Figure 4B. The levels
of LINE-1 methylation were significantly different
among the different groups, highest in the control
groups (35%) and lowest in the combined group
either at the first analysis (10%), at the second ana-
lysis (5%) (Figure 4C). These results indicate that
DNA methylation might be involved in the regulation
of some critical gene expression in the progression of
castration-resistant prostate cancer.
The methylation levels of the miR-146a promoter were
negatively associated with miR-146a expression in the
different groups
To determine whether DNA methylation was involved
in the regulation of miR-146a expression, we analyzed
the methylation of miR-146a promoter region of the dif-
ferent groups by the BSP assay. DNA was amplified
using BSP primers, and sequencing chromatograms for
the four CpG sites near and at the NF-κB binding site
were shown in Figure 5A. The 5-Aza-CdR treatment
group exhibited lower methylation levels at four CpG
sites within the miR-146a promoter in comparison to
the controls. The castration treatment and the combin-
ation treatment in the first analysis both showed the
lowest methylation levels (50%) among the groups. How-
ever, the methylation levels increased to 90% in the cas-
tration group at the second analysis, similar to the
control group. The combination group also showed high
methylation levels at all CpG sites at the second analysis,
with the exception of −444 bp and −433 bp, which were
near the NF-κB binding site and is the key region in-
volved in the transcriptional regulation of miR-146a
[22,23] (Figure 5B). Overall, the methylation status of the
the miR-146a promoter in different groups were similar to
the levels of global DNA methylation (Figure 4C), and de-
methylation at −444 bp and −433 CpG sites were negatively
associated with the expression of miR-146a, which may play
a key role in miR-146a expression, while other CpG sites
may play supportive roles in this regulatory mechanism.
Discussion and conclusions
After prostate cancer patients undergo androgen depri-
vation as the first-line initial treatment, most patients
develop to a more aggressive and androgen-independent
status, with a median survival from 2 to 3 years. However,
as the current clinical treatments for androgen-independent
disease are not ideal, a therapy that either prevents or delays
the development of AIPC is needed for these patients. In
the present study, we found that 5-Aza-CdR could delay
the emergence of lethal androgen-independent tumors in
Figure 4 The combination of 5-Aza-CdR and castration decreased the global gene methylation levels in human prostate cancer
xenograft mouse models. (A) The expression of DNMT1, 3a and 3b was measured by qRT-PCR and normalized to the expression of GAPDH in
each sample of mice (n = 6). (B) A schematic illustration of COBRA LINE-1. DNA was extracted from the xenograft tissues, treated with bisulfite,
and subjected to PCR. LINE-1 methylation level was assessed by TasI-TaqI double digestion within the 160-bp amplicon. The methylated amplicons
(TaqI positive) yielded two 80-bp DNA fragments, whereas the unmethylated amplicons (TasI positive) yielded 63- and 97-bp fragments. (C)
COBRA LINE-1 of xenograft tissues. The percentage of methylation is listed above each test. The data are the mean ± SD of one representative
experiment. Similar results were obtained in three independent experiments. *P < 0.05 and **P < 0.01 compared to the controls.
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miR-146a expression by decreasing the methylation levels of
the miR-146a promoter in an LNCaP xenograft model of
castrated mice, a result that was associated with the
inhibition of prostate cancer progression. This is the
first study to reveal potential molecular alterations by
DNA methylation inhibitors as an effective therapy
for preventing the relapse of castration-resistant pros-
tate cancer.
The conversion to an androgen-independent pheno-
type is a complex process involving multiple molecular
mechanisms. Prostate cancer cells can survive at low
levels of androgens in castrated patients via androgen re-
ceptor (AR) mutation or amplification [24], or by in-
creasing 5a-reductase activity to convert testosterone to
dihydrotestosterone [25]. In addition, epigenetic alter-
ations are the most common genome changes in pros-
tate cancer cells and are associated with defects in
gene function, contributing to carcinogenesis and help-
ing the cancer cells survive and grow under andro-
gen-independent conditions. Many specific genes are
hypermethylated and inactivated during prostate cancer
progression, including APC, MDR1, GPX3, and p16 [26],
and alterations in DNA methylation are now being used
as molecular biomarkers for prostate cancer detection,
diagnosis, and prognosis. 5-Aza-CdR, a DNMT inhibitor,
can remove methyl residues from silenced genes, result-
ing in re-expression, and has been approved for useagainst hematopoietic malignancies. This inhibitor has
also shown clinical efficacy in the treatment of meta-
static lung carcinoma, acute lymphoid leukemia, chronic
myeloid leukemia, and head and neck cancer. Further-
more, 5-Aza-CdR has been evaluated in hormone-
independent metastatic prostate cancer patients in a
phase II trial by Thibault et al. [27], and several stud-
ies have indicated the effect of 5-Aza-CdR on prostate
cancer in animal models. Studies concerning combina-
tion chemotherapy of 5-Aza-CdR and chemotherapeutic
agents have been performed, with the results suggesting
the synergistic growth suppression of 5-Aza-CdR plus
PTX in all PC cell lines [28]. In the present study,
5-Aza-CdR induced apoptosis of the androgen de-
pendent (LNCaP) and androgen-independent (PC3)
prostate cancer cells. The excessive expression of miR-
146a and the demethylation of its promoter were exclu-
sively found in both cell lines treated with 5-Aza-CdR,
which was involved apoptosis of prostate carcinoma.
Then we paid attention to if 5-Aza-CdR could delay the
progression of prostate cancer to androgen independ-
ence in vivo.
Christoph et al. ever using a transgenic adenocarcinoma
mouse model of prostate cancer demonstrated that the
combined treatment of 5-Aza-CdR plus castration signifi-
cantly prolonged survival and that 5-Aza-CdR appeared to
delay the onset of androgen-independent disease [9]; how-
ever, that animal model did not mimic the course of the
Figure 5 Comparing the methylation levels of four CpG sites
located in the miR-146a promoter collected from samples from
the different group by direct BSP sequencing. (A) Representative
genomic sequencing chromatograms of the miR-146a promoter for
each group. DNA was first treated with sodium bisulfite, and the
amplified PCR products were then directly subjected to sequencing.
The upper sequence is the untreated miR-146a promoter sequence;
the lower sequences are treated sequences in different groups. The
open boxes indicate the CpG sites. (B) Percentages of the methylation
of four CpG sites in the miR-146a promoter. The methylation
percentage of the individual CpG sites was calculated by the peak
height of methylated residues (cytosine, C) divided by the sum of
methylated and unmethylated residues (thymine, T). The methylation
rate (%) is represented as the average ratio of methylated cytosines to
total cytosines (methylated plus unmethylated) of all samples in each
group. The data are the mean ± SD, n = 4–6 mice per group. *P < 0.05
and **P < 0.01 compared to the controls.
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which 5-Aza-CdR inhibits the progression of prostate can-
cer remains unclear. Of the available human prostate can-
cer cell lines, only the LNCaP cell line is androgen
responsive, PSA secreting, and immortalized in vitro.
Thalman et al. demonstrated that the LNCaP progression
model, unlike other human prostate cancer models, shares
remarkable similarities with human prostate cancer and
can transform a subpopulation to AI clones in response to
acute or chronic androgen ablation. Based on previousstudies, we utilized the LNCaP xenograft model to evaluate
the effect of 5-Aza-CdR on the growth suppression of pros-
tate cancer in castrated male mice. We observed that,
within the initial 17 days, the xenograft tumor volumes
were decreased in response to castration compared to the
control, though the tumor volumes began to increase in
the next stage, illustrating that the LNCaP xenograft model
can mimic the course of the clinical states of the transi-
tion from initial androgen dependency to androgen inde-
pendency, which is consistent with other reports [29,30].
5-Aza-CdR treatment significantly suppressed tumor pro-
gression and delayed the regeneration of prostate cancer
cells in the later stage compared to the castration treatment
alone. Correspondingly, FPSA concentrations, an important
clinical marker of prostate cancer progression, were also
significantly down-regulated at the second stage in the
combination treatment group compared to that in either
the 5-Aza-CdR or castration alone groups. Although our
study showed an effect of 5-Aza-CdR on the delay of the
onset of androgen-independent disease in the mouse
model, further research is necessary to evaluate whether 5-
Aza-CdR can prolong survival and how long 5-Aza-CdR
can delay the onset of androgen-independent disease in the
castrated mouse model.
Additionally, we found that the expression of miR-
146a was negatively correlated with tumor volumes,
which significantly enhanced in the tumor xenografts of
5-Aza-CdR-treated mice and the androgen-dependent
stage but not the androgen-independent stage of cas-
trated mice, compared to control mice. In particular, the
expression level of miR-146a was highest in the com-
bined treatment (castration and 5-Aza-CdR), either
androgen-dependent or androgen-independent stage.
We further found the change trend of NF-κB activity,
which is one of critical transcription factors for miR-
146a expression, was consistent with miR-146a expres-
sion in tumor tissues of different groups (data not
shown). Unfortunately, we could not reveal the potential
mechanism involved in the regulation of NF-κB activity
by 5-Aza-CdR or castration in the xenograft tumors of
mice.
Since DNMT1, DNMT3A and DNMT3B are known
to be involved in de novo methylation and the mainten-
ance of methylation patterns of genes, we investigated
the expression levels of all three members of the DNMT
family. Our data clearly indicates that the DNMTs
mRNA levels were all decreased after castration at the
initial stage, yet were little changed at the later stage in
different groups compared to the control in castrated
mice. There was no a correlation between the levels of
DNMT mRNA expression and the extent of global gen-
omic DNA methylation, as measured by LINE-1 repeti-
tive sequences. We deduced that the expression of
DNMT family might have different effects on the
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onstrated that DNMT3a and DNMT3b had overlapping
functions in global remethylation during early embryo-
genesis [31]. However, the enzymes may have distinct
cell- or tissue-specific functions during later embryogen-
esis or tumorigenesis [32]. In addition, DNMT family
expressions could potentially be controlled at the post-
transcriptional level in castrated mice. Lee JY et al.
found that expression of DNMT3A and DNMT3B genes
were post-transcriptionally regulated by several micro-
RNAs, specifically miR-1741, miR-16c, and miR-222, and
miR-1632 via their 3’-UTR in cancerous ovaries of laying
hens [33]. In this respect, more studies are needed to
prove if the observed effect on DNMTs expression is
specific for prostate cancer following castration.
Moreover, we found higher methylation of global gen-
omic DNA at the later stage after castration versus the
early stage, suggesting that the expression of some im-
portant anti-oncogenes was perhaps inhibited. However,
5-Aza-CdR treatment attenuated the methylation levels
in the xenograft tumors of castrated mice at both stages.
Among the different groups, the methylation levels of
the miR-146a promoter were positively correlated with
the global methylation status and negatively associa-
ted with miR-146a expression. It was notable that the
miR-146a promoter methylation levels at the CpG site
of −444 bp and −433 bp, in which an NF-κB binding site
located, were lower than all the other CpG sites in the
combination treatment mice at the second stage. NF-κB
is one of critical transcription factors for miR-146a ex-
pression, so the methylation level of NF-κB binding re-
gion in miR-146a promoter methylation is a key regular
mechanism involved in miR-146a transcription. Hyper-
methylation of the miR-146a promoter was associated
with a loss of its expression in androgen-independent
cells, and altered patterns of methylation in these cancer
cells might represent a form of genome instability that
has been hypothesized to occur during cancer progres-
sion. The loss of mir-146a was found in high-grade
AIPC tissues but not in androgen-sensitive prostate epi-
thelium, and miR-146a was demonstrated to be a tumor-
suppressor gene in modulating HA/ROCK1-mediated
tumorigenicity in androgen-dependent prostate cancer
[12]. Our results suggest that the hypermethylation of
the miR-146a promoter may be associated with aberrant
miR-146a expression in vivo and possibly the resulting
androgen insensitivity of these cells. However, to be fully
understood, the precise mechanism of miR-146a action
(its specific gene targets) in prostate cancer progression
warrants investigation.
In conclusion, this is the first study to examine the ef-
fect of 5-Aza-CdR on the inhibition of prostate tumor
growth in a castrated animal model. We also for the first
time shed light on the molecular mechanisms underlyingthe synergistic action of 5-Aza-CdR and castration, and
our findings suggest that the epigenetic regulation of
miRNAs may play important roles in androgen-independent
progression in patients after receiving androgen ablation
therapy.
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